Clin2
NCT04153422Possibly a fitRecruiting

IVIG for small fiber nerve pain with specific antibody tests

Small Fiber NeuropathyAutoimmune Small Fiber NeuropathyInflammatory PolyneuropathyImmune-Mediated Neuropathy

Part of Brain & nervous system clinical trials.

This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be at least 18 years old
  • Have proof of small fiber neuropathy from a skin biopsy within the last 12 months (or be willing to repeat it for the study)
  • Have abnormal antibody test results for TS-HDS, FGFR3, or Plexin-D1 within the last 12 months
  • Have baseline nerve pain of at least 4 out of 10 on a pain scale, and other nerve symptom scores of at least 4 out of 10
  • Be female who is not pregnant or breastfeeding, and agree to use 2 forms of birth control or avoid heterosexual sex during treatment
  • Be able to take part safely in a study visit and follow the study plan (and understand it)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06183008Not yet recruiting· Phase 4
IVIG for painful nerve damage

This trial tests if IVIG (intravenous immunoglobulin, a treatment that helps the immune system) can reduce pain in people with small fiber nerve damage or sensory neuronopathy. You may qualify if you have had moderate to severe nerve pain for at least 4 weeks and other conditions have been ruled out.

NCT06373211Recruiting· Phase 2
Early immunotherapy for nerve damage linked to anti-Hu antibodies

This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.

Paris
NCT04589299Recruiting· Phase 4
Subcutaneous immune globulin for newly diagnosed CIDP

This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.

Aalborg
NCT04208828Recruiting
IVIG for difficult gastrointestinal auto-immune nerve symptoms

This trial tests intravenous immunoglobulin (IVIG), a donated antibody treatment, for people whose gastrointestinal (GI) “motor” symptoms are not improving with standard care and may be auto-immune related. If you’re eligible, IVIG could help calm the immune system and improve gut movement symptoms.

Louisville, Kentucky
NCT07760818Not yet recruiting· Phase 2
Study of efgartigimod for nerve damage in Sjogren's disease

This trial tests a medication called efgartigimod that may help people with Sjogren's disease who have nerve damage causing numbness, tingling, or weakness. The drug works by blocking certain antibodies that are thought to attack the nerves. It aims to improve nerve symptoms and quality of life.

NCT06752356Recruiting· Phase 3
A study of a new IVIG treatment for CIDP

This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.

Tampa, Florida

Hear when a new Small Fiber Neuropathy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.